Prof. Gary Tse
About
Dr. Gary Tse studied triple science and double mathematics at high school (best results in his School’s history; highest ever UCAS Tariff Point of 695; 2 Advanced Extension Awards; mostly 100% at AS and 100% in 11 papers for A-level). He received his Bachelor of Arts with Honours (B.A.) from the University of Cambridge (2008), Master of Arts (M.A.) from the University of Cambridge (2012), Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.) from Imperial College London (2014), Doctor of Philosophy (Ph.D.) from the University of Cambridge (2015), Master in Public Health (M.P.H.) from the University of Manchester (2017), Master of Health Management (M.H.M.) from the University of New South Wales (2019), Doctor of Medicine (M.D.) from the University of Cambridge (2022) and Doctor of Medicine (D.M.) (Admittatur ad eundem Gradum) from the University of Oxford (2022).
In China, over a period of 6 years, he established the Laboratory of Cardiovascular Physiology, Cardiovascular Analytics Group and International Health Informatics Study Network for pre-clinical, clinical and meta-analysis research, respectively. He was appointed to a Distinguished Professorship at Tianjin Medical University in 2019. In 2019, he took a sabbatical to pursue a six-month advanced fellowship at the Xiamen Cardiovascular Hospital, where he focused on catheter ablation of atrial and supraventricular arrhythmias.
Since then, Dr. Tse has returned to Tianjin Medical University, where he holds a full professorial appointment, first as Professor then Chair of Cardiology, directing cardiovascular research as Principal Investigator at its Key Laboratory. Dr. Tse has provided input on strategic planning at the institutional level under the direction of senior management. Through successfully leading and managing international studies with collaborative efforts, his team continues to deliver sustained and impactful research output. He has also developed experience in project and personnel management. In particular, his team’s ethos is the bilateral nature of mentorship, where each team member plays an important role and is encouraged to develop his or her full potential.
He holds a joint appointment as Reader (Clinical) at the Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Public Health Physician at the Public Health Directorate of Medical Council (2021) and Senior Epidemiologist at the Observational and Pragmatic Research Institute, Singapore and Optimum Patient Care, Cambridge (2020), UK.
He is a Visiting Professor at the Faculty of Health and Medical Sciences (2020) and a Research Fellow at Institute of Advanced Studies (2021), University of Surrey, and an Honorary Associate Professor at the School of Pharmacy, University College London (2022). Previously, he has held a Guest Professorship at the First Affiliated Hospital, Dalian Medical University (2018) and Honorary Professorship at Xiamen Cardiovascular Hospital, Xiamen University (2019).
Dr. Tse is the Secretary of the Cardiovascular Analytics Group, a China-United Kingdom Collaboration, Principal Investigator of the Healthcare Analytics and Clinical Informatics Group at the University of Kent, Co-Director of the International Health Informatics Study Network, and Project Coordinator of the International Brugada Electrocardiographic Indices Registry and the Catecholaminergic Polymorphic Ventricular Tachycardia Electrocardiographic Indices Registry.
He is a Medical Examiner Member of the Royal College of Pathologists, received his Membership of the Faculty of Public Health (UK), and has been elected a Fellow of the European Society of Cardiology (2016), American College of Cardiology (2017), Society for Cardiovascular Angiography and Interventions (2019), Heart Rhythm Society (2018), Royal College of Physicians and Surgeons of Glasgow (Fellowship qua Physician) (2017), Royal College of Physicians of Edinburgh (2018), Royal College of Physicians of London (2019), Royal College of Paediatrics and Child Health (2019), Faculty of Public Health (UK) (2019) and Royal College of Pathologists (2022).
He and his team have published more than 150 full peer-reviewed papers in leading journals such as the Lancet, European Heart Journal, Journal of the American College of Cardiology, Journal of the National Comprehensive Cancer Network, Pharmacological Research, Diabetes, Journal of the American Medical Directors Association, Journal of the American Medical Informatics Association, Nature npj Digital Medicine, Nature npj Regenerative Medicine, Oxidative Medicine and Cellular Longevity, Redox Biology, Circulation: Arrhythmia and Electrophysiology, Circulation: Cardiovascular Imaging, International Journal of Cardiology, European Journal of Clinical Investigation, Clinical Research in Cardiology, European Journal of Preventive Cardiology, ESC Heart Failure, Stroke, Gut, Heart, Rheumatology, Ageing Research Reviews, Journal of the American Heart Association, Heart Rhythm, Europace, Journal of Arrhythmia and JACC: Clinical Electrophysiology. Dr. Tse’s work has been recognised by conferences organised by learned societies, including the International Society of Electrocardiology, International Society for Holter and Noninvasive Electrocardiology, European Society of Cardiology, European Cardiac Arrhythmia Society, Europace, Heart Rhythm Society, Asia Pacific Heart Rhythm Society, Japanese Heart Rhythm Society and Korean Heart Rhythm Society. His H-index (Google Scholar) is 47. He is an expert reviewer for >50 international journals in cardiology, cardiac electrophysiology, cardiovascular biology and epidemiology and six grant bodies from New Zealand and Poland, Sweden and the UK. He has attracted approximately $59.7 million HKD / $51.3 million CNY / £6.24 million GBP research-related funding as a principal applicant and co-applicant.
In recognition of contributions to cardiovascular medicine, Dr. Tse was selected for the ECG Bayés Award by the International Congress of Electrocardiology for the best research output by a young investigator in 2018, The Bruce del Mar Junior Investigator Award by the International Society for Noninvasive Electrocardiology (ISHNE) in 2021, senior author of the work winning the First Prize of the Young Investigator Award (first author Dr. Sharen Lee) of the International Congress of Electrocardiology in 2021, the Young Investigator Award at the European Society of Cardiology Asia Congress 2021 (first author Dr. Sharen Lee) and the Young Investigator Award at the International Society of Electrocardiology Young Community Scientific Meeting in 2022 (first author Ms. Cheuk To Chung).
Dr. Tse was one of the 33 researchers from China listed on the World’s Top 2% Scientists Released by Stanford University for the Cardiovascular System & Hematology subfield (excluding self-citations) for the Year 2020, one of the 57 researchers for the Year 2021 and one of the 62 researchers for the Year 2022 by single year citations, and one of the 32 researchers for the Year 2022 by career long citations. He ranked 35th in the Top 100 cardiovascular researchers from China for 2022. For excellence in teaching and medical education, he was voted by medical students for the Medical Clerkship Exemplary Teaching Award and later elected to the Fellowship of the Academy of Medical Educators.
Research interests
1) Comparative drug outcomes and development of predictive models to improve risk stratification in diabetes, hypertension, atrial fibrillation, stroke, myocardial infarction, valvular heart disease and heart failure using population-based datasets
2) Cardiac remodelling in cardio-metabolic disorders
3) Mechanisms underlying ventricular arrhythmogenesis and risk stratification in Brugada syndrome, long QT syndrome, catecholaminergic polymorphic ventricular tachycardia and arrhythmogenic right ventricular dysplasia/cardiomyopathy
Teaching
Dr. Tse is passionate about involving undergraduate students in medical research, focusing on academic mentorship. He welcomes KMMS and other students who are interested in undertaking research projects by working together. Please drop him an email indicating the areas of interest.
Professional
High Impact Publications (* denotes first/corresponding author; names of undergraduate students are underlined)
H-index: 47 (Google Scholar); 42 (ResearchGate); 37 (Scopus); 36 (Web of Science)
1. Lee, T.T.L., Hui, J.M.H., Lee, Y.H.A., Satti, D.I., Shum, Y.K.L., Kiu, P.T.H., Wai, A.K.C., Liu, T., Wong, W.T., Chan, J.S.K., Cheung, B.M.Y., Wong, I.C.K., Cheng, S.H.*, Tse, G.* (2022) Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared to metformin: a population-based cohort study. Journal of the American Heart Association. PMID: 36102222. https://doi.org/10.1161/JAHA.122.026289. 5-year impact factor: 5.1.
2. Lee, S., Zhou, J., Chung, C.T., Lee, R.O.Y., Bazoukis, G., Letsas, K.P., Wong, W.T., Wong, I.C.K., Mok, N.S., Liu, T., Zhang, Q.*, Tse, G.* (2022) Comparing the performance of published risk scores in Brugada syndrome: a multi-center cohort study. Current Problems in Cardiology. 101381. PMID: 36058344. https://doi.org/10.1016/j.cpcardiol.2022.101381. Impact factor: 16.4.
3. Chan, J.S.K., Lakhani, I., Lee, T.T.L., Chou, O.H.I., Lee, Y.H.A., Cheung, Y.M., Yeung, H.W., Tang, P., Ng, K., Dee, E.C., Liu, T., Wong, W.T., Tse, G.*, Leung, F.P.* (2022) Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study. Current Problems in Cardiology. 101380. PMID: 36031015. https://doi.org/10.1016/j.cpcardiol.2022.101380. Impact factor: 16.4.
4. Zheng, Y., Zhang, N., Wang, Y., Wang, F., Li, G., Tse, G.*, Liu, T.* (2022) Association between leucocyte telomere length and the risk of atrial fibrillation: an updated systematic review and meta-analysis. Ageing Research Reviews. 81:101707. PMID: 35932977. https://doi.org/10.1016/j.arr.2022.101707. Impact factor: 11.8.
5. Chou, O.H.I., Mui, J., Chung, C.T., Radford, D., Ranjithkumar, S., Evbayekha, E., Nam, R., Pay, L., Satti, D.I., Garcia-Zamora, S., Bazoukis, G., Çinier, G., Lee, S., Vassiliou, V.S., Liu, T., Tse, G.*, Wong, I.C.K. Cardiovascular Analytics Group, the International Health Informatics Study Network (2022) COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis. Clinical Research in Cardiology. PMID: 35906423. https://doi.org/10.1007/s00392-022-02070-7. Five-year impact factor: 5.1.
6. Lee, Y.H.A., Zhou, J., Hui, J.M.H., Liu, X., Lee, T.T.L., Hui, K., Chan, J.S.K., Wai, A.K.C., Wong, W.T., Liu, T., Ng, K., Lee, S., Dee, E.C., Zhang, Q.*, Tse, G.* (2022) Risk of new-onset prostate cancer for metformin versus sulphonylurea use in type 2 diabetes mellitus: a propensity score-matched study. Journal of the National Comprehensive Cancer Network. 20(6):674-682.e15. PMID: 35714677 https://doi.org/10.6004/jnccn.2022.7010. Impact factor: 12.7.
7. Chan, J.S.K., Satti, D.I., Lee, Y.H.A., Hui, J.M.H., Lee, T.T.L., Chou, O.H.I., Wai, A.K.C., Ciobanu, A., Liu, Y., Liu, T., Roever, L., Biondi-Zoccai, G., Zhang, Q., Cheung, B.M.Y., Zhou, J.*, Tse, G.* (2022) High visit-to-visit cholesterol variability predicts new-onset heart failure and adverse cardiovascular events: a retrospective population-based cohort study. European Journal of Preventive Cardiology. PMID: 35653641. https://doi.org/10.1093/eurjpc/zwac097. Impact factor: 8.5.
8. Chou, O.H.I., Zhou, J., Lee, T.T.L., Kot, T., Lee, S., Wai, A.K.C., Wong, W.T., Zhang, Q.P., Cheng, S.H., Liu, T., Vassiliou, V.S.*, Cheung, B.M.Y.*, Tse, G.* (2022) Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. Clinical Research in Cardiology. PMID: 35333945. https://doi.org/10.1007/s00392-022-02007-0. Impact factor: 6.1.
9. Tse, G., Liu, T., Roever, L., Lee, S. (2022) The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes. 71(1):e1–e2. PMID: 34995349. https://doi.org/10.2337/db21-0686. Impact factor: 9.5.
10. Zhou, J., Lee, S., Wong, W.T., Bin Waleed, K., Leung, K.S.K., Lee, T.T.L., Wai, A.K.C., Liu, T., Chang, C., Cheung, B.M., Zhang, Q.*, Tse, G.* (2021) Gender-specific clinical risk scores incorporating blood pressure variability for predicting incident dementia. Journal of the American Medical Informatics Association. 29(2):335-347. PMID: 34643701. https://doi.org/10.1093/jamia/ocab173. Impact factor: 7.9.
11. Zhou, J., Lee, S., Wang, X., Li, Y., Wu, W.K.K., Liu, T., Cao, Z., Zeng, D.D., Leung, K.S.K., Wai, A.K.C., Wong, I.C.K., Cheung, B.M.Y., Zhang, Q.*, Tse, G.* (2021) Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. NPJ Digital Medicine. 4(1):66. PMID: 33833388. https://doi.org/10.1038/s41746-021-00433-4. Impact factor: 11.7.
12. Zhou, J., Lee, S., Guo, C.L., Chang, C., Liu, T., Leung, K.S.K., Wai, A.K.C., Cheung, B.M.Y., Tse, G.*, Zhang, Q.* (2021) Anticoagulant or antiplatelet use and severe COVID-19 disease: a propensity score matched territory-wide study. Pharmacological Research. 165:105473. PMID: 33524539. https://doi.org/10.1016/j.phrs.2021.105473. Impact factor: 10.3.
13. Zhou, J., Wang, X., Lee, S., Wu, W.K.K., Cheung, B.M.Y., Zhang, Q.*, Tse, G.* (2020) Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut. gutjnl-2020-323668. PMID: 33277346. https://doi.org/10.1136/gutjnl-2020-323668. 5-year impact factor: 31.8.
14. Tse, G.*, Zhou, J., Lee, S., Liu, T., Bazoukis, G., Mililis, P., Wong, I.C.K., Chen, C., Xia, Y., Kamakura, T., Aiba, T., Kusano, K., Zhang, Q., Letsas, K.P. (2020) Incorporating latent variables using nonnegative matrix factorization improves risk stratification in Brugada syndrome. Journal of the American Heart Association. 9(22):e012714. PMID: 33170070. https://doi.org/10.1161/JAHA.119.012714. Impact factor: 6.1.
15. Chen, C., Zhou, J., Yu, H., Zhang, Q., Lin, Y., Li, D., Yang, Y., Wang, Y., Tse, G.*, Xia, Y.* (2020) Identification of important risk factors for all-cause mortality of acquired long QT syndrome patients using random survival forests and non-negative matrix factorization. Heart Rhythm. S1547-5271(20)31033-X. PMID: 33127541. https://doi.org/10.1016/j.hrthm.2020.10.022. Impact factor: 6.8.
16. Li, X., Guan, B., Su, T., Liu, W., Chen, M., Bin Waleed, K., Guan, X., Tse, G.*, Zhu, Z.* Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. (2020) Heart. 27:heartjnl-2020-317062. PMID: 32461330. https://doi.org/10.1136/heartjnl-2020-317062. Impact factor: 7.4.
17. Li, C.K., Xu, Z., Ho, J., Lakhani, I., Liu, Y.Z., Bazoukis, G., Liu, T., Wong, W.T., Cheng, S.H., Chan, M.T., Zhang, L., Gin, T., Wong, M.C., Wong, I.C.K., Wu, W.K.K.*, Zhang, Q.*, Tse, G.* (2020) Association of NPAC score with survival after acute myocardial infarction. Atherosclerosis. 301:30-36. PMID: 32304975. https://doi.org/10.1016/j.atherosclerosis.2020.03.004. Impact factor: 6.8.
18. Wang, Y., Xiao, G., Zhang, G., Wang, B., Lin, Z., Saiwha, H.D., You, H., Lai, K., Su, M., Wen, H., Wang, J., Annest, L., Tse, G. (2020) Early Results of the Revivent TC Procedure for Treatment of Left Ventricular Aneurysm and Heart Failure Due to Ischemic Cardiomyopathy. EuroIntervention. 2020 Jan 28:EIJ-D-19-00225. PMID: 31985453. https://doi.org/10.4244/eij-d-19-00225. Impact factor: 7.7.
19. Ju, C., Lai, R.W.C., Li, K.H.C., Hung, J.K.F., Lai, J.C.N., Ho, J., Liu, Y., Tsoi, M.F., Liu, T., Cheung, B.M.Y., Wong, I.C.K., Tam, L.S., Tse, G.* (2019) Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology. PMID: 31873735. https://doi.org/10.1093/rheumatology/kez576. Impact factor: 7.0.
20. Tse, G., Gong, M., Nunez, J., Sanchis, J., Li, G., Ali-Hasan-Al-Saegh, S., Wong, W.T., Wong, S.H., Wu, W.K.K., Bazoukis, G., Yan, G.X., Lampropoulos, K., Baranchuk, A.M., Tse, L.A., Xia, Y., Liu, T., Woo, J. (2017) Frailty and mortality outcomes after percutaneous coronary intervention: a systematic review and meta-analysis. Journal of the American Medical Directors Association. pii: S1525-8610(17)30514-5. PMID: 29079033 http://dx.doi.org/10.1016/j.jamda.2017.09.002. Impact factor: 7.8.
21. Lakhani, I., Gong, M., Wong, W.T., Bazoukis, G., Lampropoulos, K., Wong, S.H., Wu, W.K.K., Wong, M.C.S., Ong, K.L., Liu, T., Tse, G.* (2018) Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. Metabolism. 83:11-17. PMID: 29410351. http://dx.doi.org/10.1016/j.metabol.2018.01.017. Impact factor: 13.9.
22. Chi, W.K., Gong, M., Bazoukis, G., Yan, B.P., Letsas, K.P., Liu, T., Baranchuk, A., Nombela-Franco, L., Dong, M.*, Tse, G.* (2018) Impact of coronary artery chronic total occlusion on arrhythmic and mortality outcomes: a systematic review and meta-analysis. JACC: Clinical Electrophysiology. 4(9):1214-1223. PMID: 30236396. https://doi.org/10.1016/j.jacep.2018.06.011. Impact factor: 6.1.